{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of 95% confidence interval (CI) was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"2.5","upperLimit":"NA","value":"11.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"DOR per IMWG criteria:time from first documentation of objective tumor (OT)response to first documentation of OTprogression or to death due to any cause, whichever occurred first.sCR: CR plus normal FLC ratio \\& absence of clonal cells in bone marrow biopsy by immunohistochemistry;CR:Negative immunofixation on serum \\& urine \\& disappearance of any soft tissue plasmacytomas\\&\\<5% plasma cells in bone marrow aspirates.VGPR: serum \\& urine M-protein(Mp) detectable by immunofixation but not on electrophoresis or \\>=90% reduction in serum Mp plus urine Mp level \\<100 mg/24 hr. PR: \\>=50% reduction of serum Mp \\& reduction in 24 hrs urinary Mp by \\>=90% or to \\<200 mg/24 hr.If serum \\& urine Mp were unmeasurable, \\>=50% decrease in difference between involved \\& uninvolved FLC levels required in place of Mp criteria. Progression: appearance of local, regional or distant disease of same type after CR or progression of pre-existing lesions. It did not include second primary malignancies of unrelated types.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 44 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 76 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG000","title":"Part 2A: PF-06863135 SC"}],"paramType":"MEDIAN","populationDescription":"mITT analysis set included all participants who have received at least one dose of study treatment. Here, \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From the first documentation of objective tumor response to first documentation of objective tumor progression or new anti-cancer therapies or death, whichever occurred first, (maximum up to 34.3 months)","title":"Part 2: Duration of Response (DOR) as Per IMWG Criteria","type":"PRIMARY","unitOfMeasure":"Months"}